Literature DB >> 3024206

Hepatic tumors: US contrast enhancement with CO2 microbubbles.

Y Matsuda, I Yabuuchi.   

Abstract

Enhancement of hepatic tumors on sonograms by injection of carbon dioxide microbubbles into the hepatic artery as a contrast material (enhanced ultrasonography) was performed in 43 patients with various histologically confirmed hepatic tumors. Enhanced sonograms were classified into five patterns according to the relative changes of the echo levels between the tumor and the nontumorous parenchyma of the liver as a result of enhancement: hyperechoic change, isoechoic change, hypoechoic change with hyperechoic rim (rim sign), marginal spotty hyperechoic change, and internal spotty hyperechoic change. Eighty-eight percent of hepatocellular carcinomas showed hyperechoic change, 70% of metastatic tumors exhibited hypoechoic change with the rim sign. The marginal spotty hyperechoic change and the internal spotty hyperechoic change were specific for cavernous hemangioma and fibrous granuloma, respectively. This method of enhancement is useful in assessing the nature of liver tumors and in the detection of small nodules in the liver.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024206     DOI: 10.1148/radiology.161.3.3024206

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

Review 1.  Recent applications of ultrasound: diagnosis and treatment of hepatocellular carcinoma.

Authors:  Hitoshi Maruyama; Masaaki Ebara
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

2.  Portal vein embolization by fine needle ethanol injection: experimental and clinical studies.

Authors:  Ming-De Lu; Jun-Wei Chen; Xiao-Yan Xie; Li-Jian Liang; Jie-Fu Huang
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

3.  Qualitative diagnosis of hepatocellular carcinoma by contrast enhanced ultrasonography using Coded Harmonic Angio with Levovist.

Authors:  Toshiko Hirai; Hajime Ohishi; Etsuko Tokuno; Miho Takahashi; Hiroshi Sakaguchi; Hiroshi Anai; Yuko Nishimoto; Shinji Hirohashi; Kimihiko Kichikawa
Journal:  J Med Ultrason (2001)       Date:  2002-03       Impact factor: 1.314

4.  Intraoperative ultrasound during ex situ liver resection.

Authors:  H Lang; K J Oldhafer; A Weimann; H J Meyer; R Pichlmayr
Journal:  Surg Endosc       Date:  1996-03       Impact factor: 4.584

5.  Clinical management of recurrent hepatocellular carcinoma.

Authors:  P H Lee; W J Lin; Y M Tsang; R H Hu; J C Sheu; M Y Lai; H C Hsu; W May; C S Lee
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

Review 6.  Current role of ultrasound for the management of hepatocellular carcinoma.

Authors:  Hitoshi Maruyama; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Dynamic contrast-enhanced ultrasound with carbon dioxide microbubbles as adjunct to arteriography of liver tumors.

Authors:  A Veltri; S Capello; B Faissola; F Spalluto; S Farinet; M Grosso
Journal:  Cardiovasc Intervent Radiol       Date:  1994 May-Jun       Impact factor: 2.740

Review 8.  Contrast-enhanced endoscopic ultrasonography in digestive diseases.

Authors:  Yoshiki Hirooka; Akihiro Itoh; Hiroki Kawashima; Eizaburo Ohno; Yuya Itoh; Yosuke Nakamura; Takeshi Hiramatsu; Hiroyuki Sugimoto; Hajime Sumi; Daijiro Hayashi; Naoki Ohmiya; Ryoji Miyahara; Masanao Nakamura; Kohei Funasaka; Masatoshi Ishigami; Yoshiaki Katano; Hidemi Goto
Journal:  J Gastroenterol       Date:  2012-09-25       Impact factor: 7.527

9.  Intraarterial digital subtraction angiography with carbon dioxide: superior detectability of arteriovenous shunting.

Authors:  T Takeda; K Ido; Y Yuasa; G Nishimura; S Hashimoto; E Kyo; S Okawa; S Nakatsuka; H Miura; S Kobayashi
Journal:  Cardiovasc Intervent Radiol       Date:  1988-04       Impact factor: 2.740

10.  Evaluation of hyperechoic liver tumors in MHTS.

Authors:  Y Kimura; R Fukada; S Katagiri; Y Matsuda
Journal:  J Med Syst       Date:  1993-08       Impact factor: 4.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.